Additionally, overexpressed LINC01714 facilitated the susceptibility of CCA cells to gemcitabine by reducing phosphorylated FOXO3-Ser318 (Figure 1B), which indicated that LINC01714 transcription promoter and gemcitabine combined with chemotherapy may have a synergistic effect on the treatment of advanced CCA patients (Shen et al., 2020). The gene discussed is FOXO3; the disease is cholangiocarcinoma.